Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.58 |
| ▸ | BAD | Q92934 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | RXRA | P19793 | 6/20 | 0.52 |
| ▸ | RXRB | P28702 | 5/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | TYR | P14679 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28631597 | 0.98 | BCL2L1 (0.56) | BCL2L1BADTSHRTP53RXRA | |
| SCHEMBL28633237 | 0.98 | BCL2L1 (0.56) | BCL2L1BADTSHRTP53RXRA | |
| SCHEMBL28987693 | 0.96 | BCL2L1 (0.54) | BCL2L1BADTSHRTP53RXRA | |
| Water SCHEMBL22788424 | 0.87 | TSHR (0.75) | BCL2L1BADTSHRTP53RXRA | |
| Water SCHEMBL8605516 | 0.87 | TSHR (0.75) | BCL2L1BADTSHRTP53RXRA | |
| SCHEMBL8070391 | 0.85 | TSHR (0.61) | BCL2L1BADTSHRTP53CA12 | |
| SCHEMBL20583 | 0.85 | — | — | |
| Water SCHEMBL27988849 | 0.85 | TSHR (0.71) | BCL2L1BADTSHRTP53RXRA | |
| SCHEMBL69873 | 0.84 | TSHR (0.80) | BCL2L1BADTSHRTP53RXRA | |
| SCHEMBL14018385 | 0.84 | TSHR (0.80) | BCL2L1BADTSHRTP53RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113237928-B | Electrochemical luminescence sensor for detecting hepatitis B virus DNA and preparation and application thereof | 重庆医科大学 | 2023-02-17 | — | — | CN | claimed |
| CN-113237928-A | Electrochemical luminescence sensor for detecting hepatitis B virus DNA and preparation and application thereof | 重庆医科大学 | 2021-08-10 | — | — | CN | claimed |
| EP-0770079-B1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-02-12 | — | — | EP | claimed |
| US-20020107251-A1 | Heterobicyclic derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-08-08 | — | — | US | claimed |
| US-6426345-B1 | PHOSPHODIESTERASE INHIBITORS; ANTIINFLAMMATORY AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-07-30 | — | — | US | claimed |
| CN-1157617-A | Heterobicyclic derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-08-20 | — | — | CN | claimed |
| EP-0770079-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-02 | — | — | EP | claimed |
| WO-1996001825-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-01-25 | — | — | WO | claimed |
| CN-113237928-B | Electrochemical luminescence sensor for detecting hepatitis B virus DNA and preparation and application thereof | 重庆医科大学 | 2023-02-17 | — | — | CN | disclosed |
| CN-114031788-B | Microporous zinc coordination polymer for propyne propylene separation and preparation method thereof | 北京工业大学 | 2022-06-14 | — | — | CN | disclosed |
| CN-113603897-B | Preparation of zinc-based metal organic framework material and selective adsorption application thereof | 北京工业大学 | 2022-06-07 | — | — | CN | disclosed |
| CN-114031788-A | Microporous zinc coordination polymer for propyne propylene separation and preparation method thereof | 北京工业大学 | 2022-02-11 | — | — | CN | disclosed |
| CN-113603897-A | Preparation of zinc-based metal organic framework material and selective adsorption application thereof | 北京工业大学 | 2021-11-05 | — | — | CN | disclosed |
| CN-113237928-A | Electrochemical luminescence sensor for detecting hepatitis B virus DNA and preparation and application thereof | 重庆医科大学 | 2021-08-10 | — | — | CN | disclosed |
| CN-1051548-C | Heterobicyclic derivatives, pharmaceutical compositions containing them, process for preparing them and their use | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-04-19 | — | — | CN | disclosed |
| CN-1157617-A | Heterobicyclic derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-08-20 | — | — | CN | disclosed |
| EP-0770079-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996001825-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-01-25 | — | — | WO | disclosed |
| US-4959387-A | ISOBENZOFURAN COMPOUNDS | SYNTEX (U.S.A.) INC. (US) | 1990-09-25 | — | — | US | disclosed |
| US-4725622-A | Mycophenolic acid derivatives in the treatment of rheumatoid arthritis | SYNTEX (U.S.A.) INC. (US) | 1988-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107251-A1 | Heterobicyclic derivatives | ARSA, ARRB1, SULT2A1 | BCL2L1 2603/4885BAD 3260/4885TSHR 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.